XML 85 R69.htm IDEA: XBRL DOCUMENT v3.25.1
Sale of Future Revenue - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended 53 Months Ended
Nov. 03, 2020
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2020
Dec. 31, 2024
Mar. 31, 2025
Disaggregation of Revenue [Line Items]            
Payments for loan acquisition costs   $ 6 $ 5      
Revenues   8,720 $ 12,053      
Royalty            
Disaggregation of Revenue [Line Items]            
Revenues   $ 0     $ 1,008  
MAM Pangolin Royalty , LLC | Maximum            
Disaggregation of Revenue [Line Items]            
Proceeds from sale of future revenue $ 125,000          
License agreement with Sunovion Pharmaceuticals, Inc.            
Disaggregation of Revenue [Line Items]            
Minimum annual royalty receivable       $ 1,000    
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty            
Disaggregation of Revenue [Line Items]            
Revenues       $ 8,000    
Monetization Agreement            
Disaggregation of Revenue [Line Items]            
Payments for loan acquisition costs $ 2,909          
Effective annual interest rate 24.90%          
Monetization Agreement | MAM Pangolin Royalty , LLC            
Disaggregation of Revenue [Line Items]            
Proceeds from sale of future revenue $ 40,000         $ 50,000
Proceeds from debt, contingent on additional milestones 75,000          
Additional proceeds from sale of future revenue $ 10,000